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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.006The proinﬂammatory response leads to various types of pathologic pathways, including the development of
preterm birth. Preterm birth occurs in 12% of deliveries in the United States and causes more than 70% of
perinatal morbidity and mortality. The most common cause of spontaneous preterm birth is intrauterine
infection in the mother. There is accumulating evidence indicating that the release of proinﬂammatory
cytokines plays a critical role in the pathogenesis of inﬂammation-associated premature delivery. We found
that the common organic solvent,N,N-dimethylacetamide (DMA), prevents endotoxin-induced preterm birth
in timed pregnant C57BL/6 embryonic day (E)15.5mice and rescues their pups from spontaneous abortion at
doses many-fold lower than those currently used clinically and in a dose-dependent fashion. We also provide
histologic evidence that DMA suppresses the endotoxin-triggered proinﬂammatory response by signiﬁcantly
attenuating inﬂammatory cell inﬁltration of placental tissue. Furthermore, immunoblotting analysis of
placental tissue harvested from our murine models revealed DMA-mediated regulation of expression of the
proinﬂammatory cytokines IL-1b, tumor necrosis factor a, and IL-6, and increased expression of the
regulatory inﬂammatory cytokine IL-10. By using in vitro studies, we provide evidence that DMA suppresses
macrophage function and that this small molecule prevents nuclear translocation of nuclear factor-kB. These
results suggest that DMA represents a newly discovered, nontoxic therapy for a broad range of inﬂammatory
disorders. (Am J Pathol 2013, 183: 422e430; http://dx.doi.org/10.1016/j.ajpath.2013.05.006)Supported by NIH grants 1 K08 HD1209 (S.E.R.) and 1 R01 NS069577
(S.E.R. and R.A.S.).
C.R.A. and S.E.R. have ﬁled a patent application for the use of DMA for
inﬂammatory conditions (US patent application number 13/536,946).Awide variety of disorders are associatedwith proinﬂammatory
responses, including sepsis,1 the fetal inﬂammatory response
syndrome,2 and preterm birth (PTB).3 Premature delivery
accounts for nearly half of long-term neurologic morbidity, and
60% to 80% of perinatal mortality, excluding infants with
congenital anomalies,3,4 and has increased in prevalence in the
UnitedStates by 20% from1990 to 2005.Unfortunately, there isstigative Pathology.
.no Food and Drug Administrationeapproved treatment for
preterm labor and existing therapies are ineffective.5
DMA Controls InﬂammationThe release of proinﬂammatory cytokines plays a critical role
in the pathogenesis of inﬂammation-associated premature
delivery.6,7 Bacteria in the gestational compartment of pregnant
women have been shown to trigger the immune system via cell
surface recognition molecules such as Toll-like receptor-2 and
Toll-like receptor-4,8,9 andT-helper cell (Th)1 cytokines such as
IL-1b and tumor necrosis factor (TNF) a.10e12 The inﬂamma-
tory response is responsible for inducing steps in the latter part of
the parturition cascade, such as decreased prostaglandin catab-
olism, functional progesterone withdrawal, increased expres-
sion of proteases, contraction-associated proteins, and increased
uterine contractile activity.13e15 Furthermore, inﬂammation can
induce the rupture of membranes and cervical ripening, known
to be mediated by matrix metalloproteinases (MMPs).16
MMP-8 in particular has been used as a bedside test to iden-
tify patients at risk for imminent preterm birth.17,18 Finally,
Gomez et al2 described the fetal inﬂammatory syndrome,which
is characterized by increased fetal plasma IL-6 levels.
In a screen for nontoxic vehicles for ongoing studies, we
discovered that N,N-dimethylacetamide (DMA) attenuates
the excessive endotoxin-triggered proinﬂammatory response
that leads to preterm delivery. DMA is an inexpensive,
common aprotic organic solvent administered in a clinical
setting at doses many-fold higher than those used in our
experiments. In the current work, we present data from both
in vivo and in vitro systems that uncovered DMA’s potential
as a novel anti-inﬂammatory agent.
Materials and Methods
Reagents
Lipopolysaccharide (LPS) (serotype 026:B6) and antibodies
against TNF a, IL-6, IL-1b, MMP-8, and NF-kB p65 were
purchased from Sigma-Aldrich (St. Louis, MO). IL-10
antibody was obtained from Epitomics (Burlingame, CA).
RAW 264.7 cells were purchased from ATCC and cell
culture media was obtained from Caisson Laboratories
(North Logan, UT). Normal goat serum was purchased from
Chemicon (Temecula, CA). Goat anti-rabbit secondaryTable 1 DMA Prevents LPS-Triggered PTB and Spontaneous Abortions
Group Control
DMA tr
0.2
Received 50 mg/kg LPS Yes Yes
Number of mice 9 7
Number of mice that delivered 8 5
Number of pups 69 47
Number of pups spontaneously aborted 30 12y
Mice were treated with LPS followed by varying does of DMA, as indicated. Sham
mice delivering was decreased signiﬁcantly at the four highest doses of DMA. The
was reduced signiﬁcantly at all ﬁve doses of DMA tested.
*P < 0.05.
yP < 0.01.
zP < 0.001.
xP < 0.0001.
The American Journal of Pathology - ajp.amjpathol.orgAlexa Fluor 595econjugated antiserum was acquired from
Molecular Probes (Eugene, OR). Lysis, loading, running,
and transfer buffers, as well as molecular weight standards
and polyvinylidene diﬂuoride membranes were purchased
from Life Technologies (Grand Island, NY). Skim milk
powder and Bradford reagent were obtained from EMD
Chemicals (Gibbstown, NJ). Anti-rabbit IgG, horseradish-
peroxidaseelinked whole antibody was purchased from GE
Healthcare (Buckinghamshire, UK), and DAPI was pur-
chased from Molecular Probes. Autoradiographic ﬁlm was
obtained from Denville Scientiﬁc (Metuchen, NJ). Stripping
buffer was purchased from Thermo Scientiﬁc (Rockford, IL).
The RNeasy Mini kit and RNAlater were purchased from
Qiagen (Valencia, CA). Amino Allyl MessageAmp II aRNA
(also called cRNA) ampliﬁcation kits were purchased from
Ambion (Austin, TX). Glyceraldehyde-3-phosphate dehy-
drogenase probes were purchased from Applied Biosystems/
Life Technology (Carlsbad, CA). SYBR Green Master Mix
was purchased from Qiagen. The Griess reagent kit was
purchased from Promega (Madison, WI). DMA was pur-
chased from Sigma-Aldrich. Purity of DMA was conﬁrmed
in one of our own laboratories by gas chromatographye
mass spectroscopy. All other reagents were purchased from
Sigma-Aldrich and VWR (Bridgeport, NJ).
Animals
Eight-week-old female C57Bl/6 mice were purchased from
Taconic Laboratories (Hudson, NY). All procedures complied
with the St. John’s University Animal Care and Utilization
Committee of the College of Pharmacy and Health Sciences.
Research was conducted according to the NIH Guide for the
Care and Use of Laboratory Animals, eighth edition, National
ResearchCouncil (US)Committee for theUpdate of theGuide
for the Care and Use of Laboratory Animals.
In Vivo Studies of the Effect of DMA on PTB
A total of 48 timed-pregnant mice weighing between 27 and
36 grams were given i.p. injections of 50 mg/kg LPSin a Dose-Dependent Fashion
eatment, mg/kg
Sham0.39 0.78 1.56 3.1
Yes Yes Yes Yes No
8 10 6 8 4
3* 2y 0y 0z 0
46 73 47 52 28
5x 4x 0x 0x 0
mice were injected with PBS in lieu of LPS. The proportion of LPS-induced
proportion of pups prematurely delivered and hence spontaneously aborted
423
Sundaram et al(serotype 026: B6; Sigma) dissolved in 500 mL PBS on E15.5
(t Z 0 hours), following previously established proto-
cols.19e21 Mice then randomly were assigned to the control
group or one of ﬁve treatment groups. At tZ0.5 hours and
tZ 10 hours they were injected with either 0.5 mL of PBS
(control group) or 0.1 mL of increasing concentrations
(6.25%, 12.5%, 25%, 50%, and 100%) of DMA (treatment
groups). In addition, a sixth group of four animals (sham
group) received an i.p. injection of 0.5 mL PBS in lieu of LPS
and the PBS injections at 0.5 and tZ 10 hours (Table 1).
Mice were autopsied at 24 hours to conﬁrm pregnancy, to
determine the number of pups retained in utero, and to
evaluate pups for congenital anomalies.
Histologic Analysis of the Effect of DMA on
Inﬂammatory Cell Inﬁltration
Placentas were harvested during necropsy and ﬁxed in 10%
buffered formalin. Fixed tissues were parafﬁn-embedded,
sectioned at 4 mm, and stained with H&E. All slides were
examined by three blinded observers (K.A., S.M., and
S.E.R.), one of whom is a practicing pathologist (S.E.R.),
and graded for extent of inﬂammatory cell inﬁltration. The
slides initially were scanned at 100 magniﬁcation to
identify any areas of active inﬂammation. The three most
active (Invitrogen, Carlsbad, CA) ﬁelds at 400 on each
slide then were used for analysis. Slides with the three most
active ﬁelds containing an average of 0 to 5 neutrophils
were graded as 1, slides with the three ﬁelds containing an
average of 6 to 50 neutrophils were graded as 2, and slides
with the three most active ﬁelds containing greater than 50
neutrophils on average were graded as 3. The pathologist
observer trained the nonpathologist observers before
grading began and concordance among the three observers
was conﬁrmed with test slides. Sections were examined with
a Nikon Eclipse 80i light microscope and images were
captured with a Nikon Digital Sight camera (Nikon, Mel-
ville, NY).
cDNA Microarray Analysis
Five additional C57BL/6 timed-pregnant mice were induced
with LPS and injected at E15.5 as described earlier. Twelve
control E15.5 mice (distinct from mice used in the in vivo
study) received a sham i.p. injection of PBS in lieu of LPS.
Placentas were collected on E16.5, 24 hours after LPS
injection or sham injection. Mice were sacriﬁced and rapidly
hysterectomized. Placentas were placed immediately in
RNAlater. Total RNA extraction was accomplished with an
RNeasy Mini kit (Qiagen). Total RNA was quantiﬁed by
measuring the absorbance at 260 nm (A260). The purity of
RNA was determined by measuring the A260/A280 ratio. The
ratio of A260 to A280 was within a range of 1.7 to 2.1 for all
samples used for RNA ampliﬁcation. RNA integrity was
assessed by performing gel electrophoresis using 1.2%
denatured agarose gels run at 100 volts (5 to 7 V/cm). Total424RNA samples displaying two sharp (28S and 18S) rRNA
bands were used for RNA ampliﬁcation.
mRNA was extracted from samples of total RNA, ampli-
ﬁed, and labeled by using the Amino Allyl MessageAmp II
aRNA ampliﬁcation kit (Ambion). Samples were quantiﬁed
with a Nanodrop D1000 spectrophotometer (NanoDrop
Technologies, Inc., Wilmington, DE). Poly(U) RNA (aRNA)
also was subjected to gel electrophoresis and samples
appearing as a smear from6 to 0.5 kbwere retested.An aliquot
of 5 to 10 mg of each aRNA sample was lyophilized and then
analyzed by a bioanalyzer (Agilent, Santa Clara, CA). Equi-
molar amounts of control samples were pooled and labeled
with Cy3 (which ﬂuoresces green), whereas samples from the
ﬁve LPS-induced mice were labeled individually with Cy5
(which ﬂuoresces red). Five hybridizations were performed.
Each arraywas hybridizedwith the pooled control sample and
a different Cy5-labeled sample.
Two color oligo arrays were designed and printed at the
cDNA Microarray Facility of the Albert Einstein College of
Medicine (Bronx, NY). Each array consists of 32,767 spots,
which includes 192 sequences for quality control of the
arrays, and represents the entire mouse genome. Arrays were
prehybridized in preheated 35% formamide, 0.5% SDS, 2%
salmon sperm DNA, and 4 sodium chloride-sodium phos-
phate-EDTAe2.5 Denhardt’s solution (Sigma-Aldrich) for
1 hour at 50C.
For hybridization, equimolar amounts of Cy3- and Cy5-
labeled aRNA were combined. The volume was adjusted to
18.5 mL, and 1.0 mL of 20 blocking buffer (1 mg/mL pol-
ydA, 10 mg/mL tRNA, and 1 mg/mL human/mouse Cot1
DNA), and 40.5 mL hybridization solution (35% formamide,
0.5% SDS in 4 SSPEe2.5 Denhardt’s) were added.
Samples then were heated at 85C to 94C for 1 minute,
vortexed, and centrifuged at 2,700  g for 2 minutes. They
were incubated at 50C for 1 hour, and then centrifuged at
13,000  g for 3 minutes. Each array then was covered with
58 mL of the supernatant from this last centrifugation of each
aRNA sample and hybridized at 50C for 20 hours.
After hybridization, arrays were washed at 25C for 5
minutes in 600 mL 2 standard saline citrate/0.1% SDS,
0.2 standard saline citrate/0.1% SDS, and 0.2 standard
saline citrate, and promptly dried and scanned, using the
GenePix 4000A microarray scanner (Axon Instruments,
Foster City, CA). The UHR Cy3 Cy5 images were acquired
with GenePix Pro software version 6.0 (Axon Instruments).
Gel Electrophoresis
Placentas were homogenized in 0.3 mL ice-cold lysis buffer
for 2minutes every 15minutes over the course of 2 hours. The
homogenates were centrifuged at 10,000  g for 5 minutes.
The protein contents of the supernatants were determined
using the Bradford assay with bovine serum albumin as the
protein standard.
A volume corresponding to 30 mg protein of each
supernatant was added to 3 mL NuPAGE LDS sample bufferajp.amjpathol.org - The American Journal of Pathology
DMA Controls Inﬂammation(4) (Invitrogen) and 1 mL NuPAGE sample reducing agent
(10). Distilled water was added until a volume of 12 mL
was reached, and the samples were reduced at 95C for 5
minutes. Gel electrophoresis was performed in an XCell
SureLock mini cell apparatus (Invitrogen) using 12-well
NuPAGE Bis-Tris gel for protein separation. The gel was
allowed to run for 45 minutes with 3-(N-morpholino)
propane sulfonic acid running buffer. Proteins then were
transferred to a polyvinylidene diﬂuoride membrane.
Immunoblotting
The polyvinylidene diﬂuoride membranes were wetted with
Tris-buffered saline with 0.1% Tween-20, pH 7.8, for 10
minutes and then blocked with 5% skim milk powder in Tris-
buffered saline with 0.1% Tween-20 solution for 2 hours.
Next, the membranes were incubated with primary antibodies
diluted in the blocker solution overnight at 4C. They were
washed with Tris-buffered saline with 0.1% Tween-20 three
times at intervals of 15 minutes at room temperature. The
membranes were incubated with a 1:1000 dilution of sec-
ondary antibody, anti-rabbit IgG, horseradish-peroxidasee
linkedwhole antibody, in blocker solution at room temperature
for 2 hours. The membranes were washed again with Tris-
buffered salinewith 0.1%Tween-20 three times for 15minutes
and treated with the ECL Plus Western blotting detection
system (GE Healthcare, Piscataway, NJ). Chemiﬂuorescence
was detected by exposure to autoradiography ﬁlm. The
membranes were stripped at room temperature, incubated with
antieglyceraldehyde-3-phosphate dehydrogenase primary
antibody (1:1000), and the steps described earlier were
repeated. Band densities were quantiﬁed using ImageJ soft-
ware (NIH, Bethesda, MD). The density values of house-
keeping protein glyceraldehyde-3-phosphate dehydrogenase
immunoblots were used for normalization.
Measurement of Nitric Oxide Production
Murine macrophage RAW264.7 cells were seeded in 6-well
plates and treated with various concentrations of DMA. At 1
hour, cells were stimulated with 0.1 mg/mL LPS. Cell super-
natants were collected at 24 hours and centrifuged at 1000 g
for 10minutes to removeﬂoating cells. Nitric oxide production
was determined by measuring nitrite concentration in the
supernatant using the Griess reagent system (Promega) as
described by the manufacturer. Brieﬂy, 50 mL of the sample
was reacted with 50 mL of sulfanilamide and 50 mL of 0.1%
N-1 naphthyl ethylenediamine dihydrochloride solutions in
water, each treatment lasted 10minutes andwas protected from
light. Absorbance was read at 540 nm using the Opsys MR
microplate reader (DYNEX technologies, Inc, Chantilly, VA).
Immunocytochemical Analysis of the Effect of DMA on
NF-kB Translocation
RAW 264.7 cells were seeded in 12-well plates and were
allowed to adhere overnight at 37C. Cells were grownwith orThe American Journal of Pathology - ajp.amjpathol.orgwithout 100 ng/mLLPS in the presence or absence of 0.01 or 1
mmol/L DMA for 2 hours. After treatments, cells were ﬁxed
with 2% phosphate-buffered formaldehyde (pH 7.4) for 15
minutes and washed three times with PBS. Cells then were
permeabilized with 0.2% Triton X-100 and nonspeciﬁc
binding sites were blockedwith 10%normal goat serum for 20
minutes. This step was followed by washing the cells with 1%
bovine serum albumin in PBS and incubation with antieNF-
kB p65 primary antibodies overnight at 4C. Incubation with
goat anti-rabbit IgG conjugated with Alexa Fluor 594 was
performed for 1 hour. Normal blocking serumwithout primary
antibody was used as a negative control. To visualize the
nuclei, cells were counterstained with DAPI. Cells were
examined under an immunoﬂuorescencemicroscope (Nikon).
Testing the Effect of DMA on Cell Viability
To measure the effect of DMA on cell viability, RAW 264.7
cells were seeded in 48-well plates and were allowed to
adhere overnight at 37C.Cells were stimulated with 1mg/mL
LPS in the presence of a series of concentrations of DMA for
24 hours. Cells then were incubated with 0.5% MTT for 2
hours at 37C. MTT then was removed and isopropanol was
added to the wells to solubilize the formazan crystals for 15
minutes. The amount of MTT formazan product was deter-
mined by measuring the absorbance of the resulting purple
solution at 570 nm using a microplate reader (Multiscan;
Thermo Electron Corporation, Milford, MA).
Statistical Analysis
For in vivo studies, the effect of the various DMA doses on
the percentage of mice experiencing preterm delivery was
determined with the Fisher exact test. Similarly, the Fisher
exact test as well as the chi-square analysis were used to
evaluate the signiﬁcance of the effect of the various DMA
doses on the percentage of pups dropped. Differences in rates
of PTB and rates of pups delivered over time were evaluated
with the log-rank (Mantel-Cox) or Gehan-Breslow-Wilcoxon
test. The U-test was used to evaluate differences in inﬂam-
matory cell inﬁltration in histologic sections. Differences in
the mean expression of cytokine proteins as determined in
immunoblots and differences in cell viability resulting from
exposure to varying concentrations of DMA were evaluated
with the Student’s t-test. Results were considered signiﬁcant
for P values less than 0.05.
For microarray analysis, the background-subtracted
signals were normalized with the locally weighted scatter-
plot smoothing algorithm using in-house Perl scripts and R
statistical package (http://www.r-project.org). Missing and
low-intensity signals (rootmean square< 300)were excluded
from the analysis. The means and SD of the signal intensity
were calculated for each gene in every group. Only genes with
signal variability of 30% (sigma/mean %) or less were
considered in the analysis. Up-regulated and down-regulated
genes were obtained from the tails of the log ratio distribution425
Figure 1 DMA prevents LPS-triggered PTB in a dose-dependent fashion.
Mice given 50 mg/kg of LPS (i.p.) were treated with 3.1, 1.56, 0.78, 0.39,
or 0.2 mg/kg DMA or PBS. All mice were observed for PTB for a period of
24 hours. A: The percentage of mice delivering at each dose of DMA over
time. The percentage of mice delivering in the groups treated with varying
doses (3.1, 1.56, 0.78, 0.39, and 0.2 mg/kg) of DMA were compared with
the percentage of mice delivering in the control group (P < 0.001,
P < 0.01, P < 0.01, P < 0.05, PZ NS, respectively). B: The dose-response
relationship between DMA and the prevention of PTB.
Sundaram et al(3 sigma from the mean) (P < 0.05) and analyzed with
Pathway Architect software (original version) (Stratagene,
LaJolla, CA).
The effect of DMA on nitric oxide production in cultured
RAW 264.7 cells was evaluated by analysis of variance.
Results
Among the eight mice responding to LPS, the mean time of
delivery was 14.3 hours. At the two highest doses of DMA,Figure 2 DMA rescues pups from LPS-triggered spontaneous abortion in a dose
abortions over time is shown (A) and the corresponding Kaplan-Meier survival cu
delivered over time was determined (P < 0.0001, P < 0.0001, P < 0.0001, P < 0.
C: The dose-response relationship between DMA and the rescue of pups from spo
4263.1 and 1.56 mg/kg, zero of eight and zero of six mice
delivered, respectively. At a dose of 0.78 mg/kg, 2 of 10
(20%) mice delivered and the average time of delivery was
19.4 hours. At 0.39 mg/kg, 3 of 8 (37.5%) mice delivered,
with 20.1 hours as the average time of delivery. At the lowest
dose (0.2 mg/kg), 5 of 7 (71.43%) mice delivered and the
average time of delivery was 16.1 hours (Table 1 and
Figure 1A). A dose-dependent relationship between DMA
and rescue of mice from PTB was observed (Figure 1B).
Statistically signiﬁcant differences in the percentage of mice
delivering in the control group and in the groups treated with
all of the doses of DMA except the lowest one were found,
with rates of delivery decreasing as the dose of DMA was
increased. Similarly, all but the lowest dose of DMA
decreased the rate of premature delivery over time.
DMA also had a signiﬁcant effect on the percentage of
pups lost to spontaneous preterm delivery. Among the LPS-
treated controls (n Z 69 pups), 30 pups (43.5%) were lost
secondary to preterm delivery. No pups were lost after
treatment with 3.1 mg/kg DMA (n Z 52) or with 1.56 mg/
kg DMA (nZ 47). After treatment with 0.78 mg/kg DMA,
4 of 73 (5.5%) pups were aborted spontaneously. At 0.39
mg/kg DMA, 5 of 46 (10.9%) pups were lost and 12 of 47
(25.5%) pups were dropped at 0.2 mg/kg (Table 1 and
Figure 2A). Kaplan-Meier survival curves for rescued pups
are shown in Figure 2B. A dose-dependent relationship
between DMA and rescue of pups from spontaneous abortion
was observed (Figure 2C). The number of pups spontane-
ously aborted in the DMA-treated groups was signiﬁcantly
lower than in the control group for all doses. All doses of
DMA tested signiﬁcantly decreased the rate of pups being
delivered prematurely over time.
A total of 362 pups were examined in this study, and 265
of them were exposed to DMA. All pups were examined for
abnormal numbers and positioning of extremities, abnormal
craniofacial development, and abdominal wall defects. None
of the mentioned anomalies was found. Moreover, no
differences in gross appearance between pups born to
DMA-treated versus DMA-untreated dams were identiﬁed.
Harvested placentas from mice subjected to sham injec-
tions (n Z 4), LPS plus PBS (n Z 4) and LPS plus DMA-dependent fashion. The cumulative percentage of pups lost to spontaneous
rves are shown (B). The effect of varying doses of DMA on the rate of pups
0001, and P < 0.01, corresponding to highest to lowest dose, respectively).
ntaneous abortion.
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Figure 3 DMA suppresses recruitment of inﬂammatory cells to the
placental labyrinth in LPS-treated mice. Placentas were harvested rapidly
and ﬁxed in 10% buffered formalin from three different groups of animals:
sham control mice treated with PBS only (n Z 4) (A), mice treated with
LPS and PBS (nZ 4) (B), and mice treated with LPS and 1.56 mg/kg DMA
(n Z 4) (C). For histologic analysis, ﬁxed tissues were dehydrated and
parafﬁn embedded, sectioned at 4 mm, and stained with H&E. Inﬂammatory
cell inﬁltrates were graded as described. Numbers of polymorphonuclear
neutrophils in sections of mouse placental labyrinth tissue from mice
treated with LPS were compared with those in sham controls treated with
PBS only (P < 0.01) and with those from mice rescued from LPS-induced
PTB with 1.56 mg/kg DMA (P < 0.01) (D). Insets: Higher magniﬁcation
(600), showing increased number of inﬂammatory cells in LPS-stimulated
tissue (B compared to A) and relatively decreased number of inﬂammatory
cells resulting from treatment with DMA (C compared to B).
Figure 4 DMA suppresses expression of placental inﬂammatory
signaling molecules in LPS-treated mice. Placental tissue lysates from LPS-
induced mice (nZ 4) and LPS-treated mice rescued from PTB with 1.56 mg/
kg DMA (nZ 4) were subjected to gel electrophoresis and immunoblotting.
Band densities from control mice induced to PTB were normalized to 1.0 and
compared with band densities from rescued mice after probing Western
blots with antibodies directed against IL-1b (P < 0.01), TNF a (P < 0.001),
and IL-6 (P < 0.05) (A); MMP-8 (P < 0.05) (B), and IL-10 (P < 0.001) (C).
Glyceraldehyde-3-phosphate dehydrogenase was used for gel loading
controls (lower bands). *P < 0.05, **P < 0.01, and ***P < 0.001.
DMA Controls Inﬂammation(n Z 4), showed vastly different degrees of labyrinthine
inﬂammatory cell recruitment. Figure 3C shows a represen-
tative microscopic section of placental labyrinth collected
from amouse treatedwith LPS, but then rescued from preterm
delivery with 1.56 mg/kg DMA. Inﬂammatory cells are rare.
In fact, the histopathologic picture is similar to the represen-
tative micrograph produced with a placenta removed from
a sham-injected mouse treated with only PBS (Figure 3A). A
representative section from a mouse that developed preterm
labor and delivery subsequent to treatment with LPS, in
contrast, shows a dense collection of polymorphonuclear
neutrophils (Figure 3B), obliterating the normal labyrinthine
architecture. The results of a graded quantitative analysis
performed by three blinded observers (K.A., S.M., and
S.E.R.), including a placental pathologist (S.E.R.), are shown
in Figure 3D. The increase in the number of inﬂammatory
cells in placentas from LPS plus PBS-treated mice as
compared with sham animals is statistically signiﬁcant (P <
0.01). Similarly, the reduction in the number of leukocytes in
placentas from mice treated with LPS, but ultimately rescued
fromPTBwithDMA, as comparedwithmice induced to labor
with LPS, was highly signiﬁcant (P < 0.01).
Microarray analysis of mRNA from placental labyrin-
thine tissue harvested from mice induced to labor with LPS
as compared with sham controls revealed activation of
a network of inﬂammatory cytokines centered on IL-1b
(Supplemental Table S1 and Supplemental Figure S1).
Microarray data were deposited in Gene Express Omni-
bus (http://www.ncbi.nlm.nih.gov/geo; accession numberThe American Journal of Pathology - ajp.amjpathol.orgpending). From these investigations of global differential
gene expression, IL-1b, TNF a, IL-6, and IL-10 were
selected for testing for changes in expression at the protein
level resulting from DMA rescue from LPS-induced PTB.
As compared with placentas from mice that developed
LPS-triggered PTB, placentas from DMA rescued mice had
signiﬁcantly reduced expression of IL-1b, TNF a, and IL-6
(Figure 4A). We hypothesized that DMA attenuated LPS-
induced changes in the uterine cervix extracellular matrix
that accompany labor. Levels of MMP-8 in placental tissue
extracts from mice rescued from preterm birth with DMA
were reduced in comparison with MMP-8 levels in mice that
developed preterm delivery (Figure 4B). Importantly, IL-10
expression increased signiﬁcantly more in placental tissue
harvested from mice rescued from PTB with DMA as
compared with control mice induced to labor with LPS
(Figure 4C).
Next, we investigated whether the anti-inﬂammatory
properties of DMA we had observed in vivo could be attrib-
uted to the effect of this compound on macrophages.
We showed that DMA suppresses macrophage bactericidal
activity in the presence of LPS stimulation in cultured
RAW 264.7 cells (Figure 5). LPS stimulation in RAW 264.7427
Figure 5 DMA suppresses nitric oxide (NO) synthesis in endotoxin-
stimulated macrophages. RAW 264.7 cells were seeded in six-well plates
in the absence or presence of a series of DMA concentrations and LPS. Nitric
oxide production was measured using a Griess reagent kit, following the
manufacturer’s instructions. Analysis of variance showed a signiﬁcant
effect of DMA on macrophage function (P < 0.0001).
Sundaram et alcells induced activation of the NF-kB signaling pathway,
which is critical in cytokine release.22 Figure 6 shows that
immunoreactivity for the p65 unit of NF-kB in untreated cells
was localized primarily in the cytoplasm, as indicated by
a prominent red stain and a distinct hollow in the nucleus.
However, treatment with LPS led to translocation of NF-kB
into the nucleus (Figure 6). LPS-stimulated cells treated
with DMA at concentrations of 0.01 mmol/L and 1 mmol/L
displayed signiﬁcantly reduced nuclear staining in compar-
ison with cells treated with LPS alone, with greater inhibition
of NF-kB translocation into the nucleus with a higher
concentration of DMA (Figure 6). To conﬁrm that DMA did
not affect cell viability at the concentrations we used, cells
also were grown in the absence or presence of LPS and treated
with DMA concentrations ranging from 0.1 to 10 mmol/L. No
signiﬁcant effect on cell viability was detected at any of these
concentrations (Supplemental Figure S2).Figure 6 DMA inhibits nuclear translocation of NF-kB in endotoxin-
stimulated macrophages. RAW 264.7 cells were seeded in 12-well plates
with or without LPS for 24 hours in the absence or presence of DMA
(concentration of DMA is indicated). Translocation of NF-kB was assessed
by immunostaining the cells with antieNF-kB antibody (red). DAPI stain
was used to visualize nuclei (blue; boxed areas). Scale bars: 10 mm.Discussion
The data presented indicate that DMA signiﬁcantly attenu-
ates the proinﬂammatory response mediated by LPS in
timed-pregnant E15.5 mice. In the histologic analysis of
placental labyrinthine tissues, DMA abolished the robust
inﬂammatory cell inﬁltrate triggered by LPS. Immunoblot-
ting analysis revealed that expression levels of the proin-
ﬂammatory cytokines IL-1b, TNF a, and IL-6 in placentas
from LPS-induced mice are decreased signiﬁcantly by
DMA. Moreover, DMA increased expression of the anti-
inﬂammatory mediator, IL-10. Finally, DMA suppressed
nitric oxide production and nuclear translocation of NF-kB
in cultured macrophages.
DMA currently is used as a cryopreservative for platelets23
and a solvent for a novel antiretroviral agent.24 DMA is
metabolized ﬁrst to monomethylacetamide and then deme-
thylated further to acetamide. Although long-term exposure
to acetamide has been shown to cause liver cancer in428rats,25 DMA is not carcinogenic. It does not affect P450-
dependent monooxygenase or phase II enzyme activities
and has no signiﬁcant effect on liver mixed-function oxidase
and cytochrome c reductase activities.26 On the other hand,
with prolonged exposure, DMA causes liver injury in
humans.27 Importantly, it has been reported that DMA, when
used as a vehicle for intravenous busulfan, does not produce
adverse effects in pediatric oncologic patients at doses many-
fold higher than those shown to suppress inﬂammation in this
study.28
At doses high enough to produce toxic effects in the
mothers, DMA causes embryotoxicity in sensitive species,
namely rabbits.29 In rats, on the other hand, no observed
adverse effects were seen in fetuses until exposure to inhaled
amounts of DMA reached levels high enough to produce
toxic effects in the mothers.30 In this study, 265 pups were
directly examined and not one showed evidence of congen-
ital anomalies.
We used a combination of in vivo and in vitro approaches
in the current study to test the efﬁcacy of DMA as a toco-
lytic agent and to investigate its mechanism of action. Our
well-established murine model of infection-associated
birth31e36 has the advantage of allowing tight experimental
control. On the other hand, by injecting LPS i.p. we have
simulated systemic infection, rather than ascending infection
per se. In future work, it will be interesting to test whether
similar results are obtained when LPS is administered in the
uterine horn. Data from both our in vivo model and our
in vitro experiments support our hypothesis that DMA’s
ability to prevent preterm birth results from its suppressive
effect on the inﬂammatory cascade. We note with interest
that in recent literature the widely used poly (ADP-ribose)
polymerase inhibitor PJ-34 also been found to suppressajp.amjpathol.org - The American Journal of Pathology
DMA Controls Inﬂammationinﬂammation in various systems, including LPS-induced
lung injury37 and to inhibit NF-kB activation.38 PJ-34
contains a DMA moiety; one might speculate whether the
anti-inﬂammatory properties of the poly (ADP-ribose)
polymerase inhibitor partially are explained by this aspect of
its molecular structure.
A method of attenuating the excessive inﬂammatory
response triggered by the Toll-like receptors represents a
novel approach to the treatment of a variety of inﬂammatory
disorders, including sepsis.39,40 DMA has a clear therapeutic
advantage over known anti-inﬂammatory agents, such as
TNF a monoclonal antibodies and nitric oxide synthase
inhibitors, which decrease the host’s ability to ﬁght off
infections.38 In fact, bacterial clearance is improved when
overexuberant inﬂammation is held in check, as shown by the
favorable effect obtained when Toll-like receptorelinked
sphingosine kinase is inhibited.41 Because inﬂammation is
implicated in an extremely broad spectrum of disorders,
including Alzheimer disease, cardiovascular disease, and
diabetes mellitus,42e55 the potential clinical impact of this
molecule as an anti-inﬂammatory agent is striking.Acknowledgments
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